Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b dose-escalation and expansion of immunotherapy combinations in triple negative breast cancer
jRCT2080224559Phase 1Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of spartalizumab, ieramilimab, taminadenant, capmatinib, lacnotuzumab and 1 more in triple-negative breast cancer (TNBC) (4 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability of spartalizumab + LAG525 combinations. Started Feb 2019; status: completed.
02
Drugs
spartalizumabieramilimabtaminadenantcapmatiniblacnotuzumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2080224559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224559.